Janux Therapeutics, Inc. (JANX) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy Transcript
Janux Therapeutics held a conference call discussing Phase 1 healthy-volunteer data for JANX011 and its autoimmune development strategy. The provided excerpt contains the call title and participant information but no details about the data or strategy.
Why it matters — The call concerns JANX011’s early clinical data and the company’s autoimmune development plans, though the excerpt gives no further substance to assess.